CuraSen Therapeutics, Inc.

CuraSen Therapeutics, Inc. is a biopharmaceutical startup founded in 2016 dedicated to revolutionizing therapies for neurodegenerative diseases, such as Parkinson’s and Alzheimer’s. The company’s slogan, "Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN," captures its mission to bring hope to patients and their families. Unlike conventional approaches, CuraSen focuses on restoring a key functionality to a pathway lost early in the degenerating brain, particularly the locus coeruleus (LC), believed to be the ‘hypocenter’ of neurodegeneration. CuraSen’s groundbreaking approach has attracted significant funding, with a recent $5.80M grant investment from the Alzheimer's Drug Discovery Foundation in October 2023. Its impressive team, backed by renowned investors including New Leaf Venture Partners, Longitude Capital, Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital, reflects the confidence in the company’s potential to make a meaningful impact in the biotechnology industry. CuraSen's innovative therapeutic approach and the successful progression of its first new chemical entity, CST-2032, to clinical trials in September 2020 position the company as a promising player in the biopharmaceutical space. With its commitment to rethinking the treatment of neurodegenerative diseases, CuraSen has the potential to address the growing burden of such diseases on millions of individuals and their families, ultimately reshaping the landscape of neurodegenerative disease treatment.